Etg Neuroscience Sp. z o.o.

Warsaw 27 trials 13 recruiting

27 Registered trials

13 Currently recruiting

Organisation

Etg Neuroscience Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100049341

Address

Ul. Wynalazek 4, 02-677, Poland

Departments

.
#40705: N/A
#616001 Neurologia
#616001;neurology
301-122: ETG Neuroscience
ETG Neuroscience
ETG NEUROSCIENCE Sp. z. o.o.
N/A
NA
Neurology
Ośrodek Badań Klinicznych

Clinical trials at this site (27)

Search interface

A clinical trial to assess the safety of EXV-802 and EXV-801 and how well they work to reduce agitation symptoms in people with Alzheimer's … Pending

2024-517388-22-00 Agitation in Alzheimer's Disease Dementia 10
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Recruiting

2025-523950-15-01 Generalized Myasthenia Gravis 4 2026-05-29
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Recruiting

2024-511101-28-00 Episodic Migraine Chronic Migraine 4 2026-02-24
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting

2024-512904-21-00 Migraine 4 2025-12-10
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-12
A Phase 3b open-label, randomised study of IPX203 in subjects with advanced Parkinson’s disease and motor fluctuations - ADIP study Recruiting

2025-521772-57-00 Motor fluctuations in advanced Parkinson’s disease 5 2025-11-06
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting

2024-515682-34-00 Chronic migraine 5 2025-10-06
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting

2024-515715-22-00 Episodic migraine 5 2025-10-06
A study of IPN10200 for the treatment of cervical dystonia in adults Recruiting

2024-519248-34-00 Cervical Dystonia 4 2025-06-17
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Recruiting

2023-508817-18-00 Perennial Allergic Rhinitis (PAR) 5 2024-10-08
A study with eptinezumab in children and adolescents (6 to 17 years) with chronic or episodic migraine (REJOIN) Recruiting

2022-502917-27-00 Migraine 5 2023-03-07
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PROSPECT-2) Recruiting

2024-510656-13-00 Migraine 5 2022-11-08
Phase 2 Study of CVN424 Ended

2024-516811-25-00 Parkinson Disease 4 2025-05-15
RCT of Medical Cannabis Aerosol for DPNP Treatment Ended

2023-508932-68-00 Diabetic Peripheral Neuropathic Pain 4 2024-11-14
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim… Ended

2023-506183-13-00 Alzheimer’s Disease 4 2024-03-29
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
“A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended

2023-503289-22-00 Relapsing Multiple Sclerosis 4 2024-07-05
MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended

2023-506425-12-00 Uncontrolled and Resistant Hypertension 5 2024-04-17
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease Ended

2024-515177-94-00 Parkinson's Disease 4 2023-06-21